ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
Robberecht W, Bednarik J, Bourgeois P, van Hees J, Carton H, 1989. Myasthenic syndrome caused by direct effect of chloroquine on neuromuscular junction. Arch Neurol 46: 464–468.
-
2.
Fischer PR, Walker E, 2002. Myasthenia and malaria medicines. J Travel Med 9: 267–268.
-
3.
Vinetz JM, Cain J, Baunkeua V, Eastman RT, Fidock D, 2010. Chemotherapy of malaria. Brunton L, Chalmer B, Knollman B, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 12th edition. New York: McGraw-Hill Professional, 1383–1418.
-
4.
Bateman DN, Dyson EH, 1986. Quinine toxicity. Adverse Drug React Acute Poisoning Rev 5: 215–233.
-
5.
Dondorp A, Nosten F, Stepniewska K, Day N, White N, 2005. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet 366: 717–725.
-
6.
World Health Organization, 2010. WHO Guidelines for the Treatment of Malaria. 2nd edition. Geneva: World Health Organization.
-
7.
Bedlack RS, Simel DL, Bosworth H, Samsa G, Tucker-Lipscomb B, Sanders DB, 1968–1970. Quantitative myasthenia gravis score: assessment of responsiveness and longitudinal validity. Neurology 64: 1968–1970.
-
8.
Karbwang J, Tin T, Rimchala W, Sukontason K, Namsiripongpun V, Thanavibul A, Na-Bangchang K, Laothavorn P, Bunnag D, Harinasuta T, 1995. Comparison of artemether and quinine in the treatment of severe falciparum malaria in south-east Thailand. Trans R Soc Trop Med Hyg 89: 668–671.
-
9.
Dondorp AM, Fanello CI, Hendriksen IC, Gomes E, Seni A, Chhaganlal KD, Bojang K, Olaosebikan R, Anunobi N, Maitland K, Kivaya E, Agbenyega T, Nguah SB, Evans J, Gesase S, Kahabuka C, Mtove G, Nadjm B, Deen J, Mwanga-Amumpaire J, Nansumba M, Karema C, Umulisa N, Uwimana A, Mokuolu OA, Adedoyin OT, Johnson WB, Tshefu AK, Onyamboko MA, Sakulthaew T, Ngum WP, Silamut K, Stepniewska K, Woodrow CJ, Bethell D, Wills B, Oneko M, Peto TE, von Seidlein L, Day NP, White NJ, 2010. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomized trial. Lancet 376: 1647–1657.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 2 | 2 | 2 |
| Full Text Views | 286 | 91 | 1 |
| PDF Downloads | 32 | 17 | 1 |
Artesunate for Severe Acute Plasmodium falciparum Infection in a Patient with Myasthenia Gravis
We report a case of severe malaria in a patient with underlying myasthenia gravis who was successfully treated with artesunate. The outcome was favorable. Artesunate seems to be a good option for patients with underlying myasthenia gravis disease because they benefit from a better toxicity profile than quinine.
Author Notes
Authors' addresses: Nathalie Dournon, Eric Caumes, and Stéphane Jauréguiberry, Infectious and Tropical Diseases Unit, Pitié-Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris, Paris 75013, France, E-mails: na_dournon@hotmail.com, eric.caumes@psl.aphp.fr, and stephane.jaureguiberry@psl.aphp.fr. Pierre Buffet, Parasitology and Mycology Unit, and French National Center for Metropolitan Malaria, Pitié-Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris, Paris 75013, France; Université Pierre et Marie Curie, Unite Mixte de Recherche 945, Paris 6, France; and Pasteur Institute, Paris 75015, E-mail: pabuffet@gmail.com. Bernard Clair, General Intensive Care Unit, Raymond Poincaré Hospital, Assistance Publique-Hôpitaux, Garches, France, E-mail: bernard.clair@rpc.aphp.fr.